PolyPeptide Group to price IPO above mids
The IPO of PolyPeptide Group, the Swiss pharmaceutical ingredients company, is set to be priced at Sfr64, above the midpoint of the initial Sfr57 to Sfr68 range, according to sources close to the deal.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: